JP2016510795A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510795A5 JP2016510795A5 JP2015562201A JP2015562201A JP2016510795A5 JP 2016510795 A5 JP2016510795 A5 JP 2016510795A5 JP 2015562201 A JP2015562201 A JP 2015562201A JP 2015562201 A JP2015562201 A JP 2015562201A JP 2016510795 A5 JP2016510795 A5 JP 2016510795A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- disease
- composition according
- patient
- diabetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 30
- 206010012601 diabetes mellitus Diseases 0.000 claims 17
- 208000020832 chronic kidney disease Diseases 0.000 claims 16
- 206010001580 Albuminuria Diseases 0.000 claims 15
- 230000002526 effect on cardiovascular system Effects 0.000 claims 15
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 12
- 102000009027 Albumins Human genes 0.000 claims 11
- 108010088751 Albumins Proteins 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 239000013543 active substance Substances 0.000 claims 10
- 239000003472 antidiabetic agent Substances 0.000 claims 10
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 10
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 10
- 208000017169 kidney disease Diseases 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 claims 8
- 208000006011 Stroke Diseases 0.000 claims 8
- 210000003734 kidney Anatomy 0.000 claims 8
- 229960002397 linagliptin Drugs 0.000 claims 8
- 208000010125 myocardial infarction Diseases 0.000 claims 8
- 108060006698 EGF receptor Proteins 0.000 claims 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 6
- 239000008280 blood Substances 0.000 claims 6
- 210000004369 blood Anatomy 0.000 claims 6
- 239000008103 glucose Substances 0.000 claims 6
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 6
- 229960003105 metformin Drugs 0.000 claims 6
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 6
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 6
- 210000002700 urine Anatomy 0.000 claims 6
- 102000004877 Insulin Human genes 0.000 claims 5
- 108090001061 Insulin Proteins 0.000 claims 5
- 229940127003 anti-diabetic drug Drugs 0.000 claims 5
- 208000029078 coronary artery disease Diseases 0.000 claims 5
- 229940109239 creatinine Drugs 0.000 claims 5
- 201000000523 end stage renal failure Diseases 0.000 claims 5
- 230000002008 hemorrhagic effect Effects 0.000 claims 5
- 229940125396 insulin Drugs 0.000 claims 5
- 210000004185 liver Anatomy 0.000 claims 5
- 201000009104 prediabetes syndrome Diseases 0.000 claims 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims 4
- 208000014882 Carotid artery disease Diseases 0.000 claims 4
- 208000002705 Glucose Intolerance Diseases 0.000 claims 4
- 229940100389 Sulfonylurea Drugs 0.000 claims 4
- 230000001934 delay Effects 0.000 claims 4
- 230000002641 glycemic effect Effects 0.000 claims 4
- 230000000302 ischemic effect Effects 0.000 claims 4
- 201000006370 kidney failure Diseases 0.000 claims 4
- 206010002388 Angina unstable Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 3
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 3
- 208000017442 Retinal disease Diseases 0.000 claims 3
- 206010038923 Retinopathy Diseases 0.000 claims 3
- 208000007814 Unstable Angina Diseases 0.000 claims 3
- 210000000577 adipose tissue Anatomy 0.000 claims 3
- 230000003178 anti-diabetic effect Effects 0.000 claims 3
- 229940125708 antidiabetic agent Drugs 0.000 claims 3
- 230000037396 body weight Effects 0.000 claims 3
- 238000002648 combination therapy Methods 0.000 claims 3
- 235000005911 diet Nutrition 0.000 claims 3
- 230000037213 diet Effects 0.000 claims 3
- 208000028208 end stage renal disease Diseases 0.000 claims 3
- 201000001421 hyperglycemia Diseases 0.000 claims 3
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 3
- 201000001119 neuropathy Diseases 0.000 claims 3
- 230000007823 neuropathy Effects 0.000 claims 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims 3
- 229960005095 pioglitazone Drugs 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 201000001474 proteinuria Diseases 0.000 claims 3
- 230000008085 renal dysfunction Effects 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 3
- 230000002792 vascular Effects 0.000 claims 3
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 2
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000032382 Ischaemic stroke Diseases 0.000 claims 2
- 206010054805 Macroangiopathy Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 2
- 206010062237 Renal impairment Diseases 0.000 claims 2
- 206010042434 Sudden death Diseases 0.000 claims 2
- 229940123464 Thiazolidinedione Drugs 0.000 claims 2
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 229960002632 acarbose Drugs 0.000 claims 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims 2
- 210000001789 adipocyte Anatomy 0.000 claims 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 2
- 239000003146 anticoagulant agent Substances 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- 230000003915 cell function Effects 0.000 claims 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000008694 endothelial dysfunction Effects 0.000 claims 2
- 230000024924 glomerular filtration Effects 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 231100000225 lethality Toxicity 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 210000000663 muscle cell Anatomy 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 208000030613 peripheral artery disease Diseases 0.000 claims 2
- 230000000291 postprandial effect Effects 0.000 claims 2
- 230000000250 revascularization Effects 0.000 claims 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims 2
- 229960001729 voglibose Drugs 0.000 claims 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 102000008873 Angiotensin II receptor Human genes 0.000 claims 1
- 108050000824 Angiotensin II receptor Proteins 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000008960 Diabetic foot Diseases 0.000 claims 1
- 206010056340 Diabetic ulcer Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000027534 Emotional disease Diseases 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 claims 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 claims 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 208000001280 Prediabetic State Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000007718 Stable Angina Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 108010028144 alpha-Glucosidases Proteins 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 230000000702 anti-platelet effect Effects 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 230000003293 cardioprotective effect Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 230000006999 cognitive decline Effects 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 239000004026 insulin derivative Substances 0.000 claims 1
- 230000003914 insulin secretion Effects 0.000 claims 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 230000005977 kidney dysfunction Effects 0.000 claims 1
- 230000028252 learning or memory Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- 229960000698 nateglinide Drugs 0.000 claims 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 231100001160 nonlethal Toxicity 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 239000003087 receptor blocking agent Substances 0.000 claims 1
- 229960002354 repaglinide Drugs 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 230000033764 rhythmic process Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 238000011125 single therapy Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 229960005187 telmisartan Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 150000001467 thiazolidinediones Chemical class 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13159624 | 2013-03-15 | ||
| EP13159624.9 | 2013-03-15 | ||
| EP13177311.1 | 2013-07-19 | ||
| EP13177311 | 2013-07-19 | ||
| PCT/EP2014/055113 WO2014140284A1 (en) | 2013-03-15 | 2014-03-14 | Use of linagliptin in cardio- and renoprotective antidiabetic therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019022289A Division JP2019112409A (ja) | 2013-03-15 | 2019-02-12 | 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016510795A JP2016510795A (ja) | 2016-04-11 |
| JP2016510795A5 true JP2016510795A5 (enExample) | 2017-04-20 |
Family
ID=50277246
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562201A Pending JP2016510795A (ja) | 2013-03-15 | 2014-03-14 | 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用 |
| JP2019022289A Pending JP2019112409A (ja) | 2013-03-15 | 2019-02-12 | 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用 |
| JP2021030485A Pending JP2021095409A (ja) | 2013-03-15 | 2021-02-26 | 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用 |
| JP2025074372A Pending JP2025115998A (ja) | 2013-03-15 | 2025-04-28 | 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019022289A Pending JP2019112409A (ja) | 2013-03-15 | 2019-02-12 | 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用 |
| JP2021030485A Pending JP2021095409A (ja) | 2013-03-15 | 2021-02-26 | 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用 |
| JP2025074372A Pending JP2025115998A (ja) | 2013-03-15 | 2025-04-28 | 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (9) | US20140274889A1 (enExample) |
| EP (4) | EP4364796A3 (enExample) |
| JP (4) | JP2016510795A (enExample) |
| KR (2) | KR20150128726A (enExample) |
| CN (2) | CN110075098A (enExample) |
| AU (2) | AU2014230096C1 (enExample) |
| BR (1) | BR112015020209A2 (enExample) |
| CA (1) | CA2903577C (enExample) |
| CL (1) | CL2015002369A1 (enExample) |
| EA (1) | EA037712B1 (enExample) |
| IL (1) | IL240064A0 (enExample) |
| MX (2) | MX2015011466A (enExample) |
| PH (1) | PH12015502042A1 (enExample) |
| WO (1) | WO2014140284A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| BRPI0711558A2 (pt) | 2006-05-04 | 2011-11-08 | Boeringer Ingelheim Internat Gmbh | polimorfos |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| PH12012501037A1 (en) | 2009-11-27 | 2013-01-14 | Boehringer Ingelheim Int | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
| CA2797310C (en) | 2010-05-05 | 2020-03-31 | Boehringer Ingelheim International Gmbh | Glp-1 receptor agonist and dpp-4 inhibitor combination therapy |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| EP4151218A1 (en) | 2012-05-14 | 2023-03-22 | Boehringer Ingelheim International GmbH | Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis |
| US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| US9968659B2 (en) | 2016-03-04 | 2018-05-15 | Novo Nordisk A/S | Liraglutide in cardiovascular conditions |
| JPWO2017170434A1 (ja) * | 2016-03-28 | 2019-01-31 | インターセプト ファーマシューティカルズ， インコーポレイテッド | Ｆｘｒアゴニストとａｒｂの組み合わせ医薬 |
| WO2017211979A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
| EP3823625A1 (en) * | 2018-07-17 | 2021-05-26 | Boehringer Ingelheim International GmbH | Cardio- and renosafe antidiabetic therapy |
| US20210299129A1 (en) * | 2018-07-17 | 2021-09-30 | Boehringer Ingelheim International Gmbh | Cardiosafe Antidiabetic Therapy |
| AU2019408336B2 (en) * | 2018-12-18 | 2022-03-10 | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | Phenylpyrrolidine compound and use thereof |
| WO2022244846A1 (ja) * | 2021-05-19 | 2022-11-24 | Kagami株式会社 | 細胞増殖の調整のための組成物及び細胞増殖の調整方法 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| TW225528B (enExample) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| SK286975B6 (sk) | 2001-02-24 | 2009-08-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xantínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| EP1532149B9 (de) | 2002-08-21 | 2011-04-20 | Boehringer Ingelheim Pharma GmbH & Co. KG | 8-[3-amino-piperidin-1-yl] -xanthine, deren herstellung und deren verwendung als arzneimittel |
| DE10238470A1 (de) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| DE10238477A1 (de) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| DE10251927A1 (de) | 2002-11-08 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| DE10254304A1 (de) | 2002-11-21 | 2004-06-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| UY28103A1 (es) | 2002-12-03 | 2004-06-30 | Boehringer Ingelheim Pharma | Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos |
| DE10327439A1 (de) | 2003-06-18 | 2005-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| DE10355304A1 (de) | 2003-11-27 | 2005-06-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| DE10359098A1 (de) | 2003-12-17 | 2005-07-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-(Piperazin-1-yl)- und 2-([1,4]Diazepan-1-yl)-imidazo[4,5-d]pyridazin-4-one, deren Herstellung und deren Verwendung als Arzneimittel |
| DE10360835A1 (de) | 2003-12-23 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel |
| CN102199151A (zh) | 2004-02-18 | 2011-09-28 | 贝林格尔.英格海姆国际有限公司 | 8-[3-氨基-哌啶-1-基]-黄嘌呤、制备及用途 |
| DE102004009039A1 (de) | 2004-02-23 | 2005-09-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel |
| EP1740589A1 (de) | 2004-04-10 | 2007-01-10 | Boehringer Ingelheim International GmbH | Neue 2-amino-imidazo[4,5-d]pyridazin-4-one und 2-amino-imidazo[4,5-c]pyridin-4-one, deren herstellung und deren verwendung als arzneimittel |
| DE102004022970A1 (de) | 2004-05-10 | 2005-12-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazolderivate, deren Herstellung und deren Verwendung als Intermediate zur Herstellung von Arzneimitteln und Pestiziden |
| DE102004043944A1 (de) | 2004-09-11 | 2006-03-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004044221A1 (de) | 2004-09-14 | 2006-03-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| RU2007116869A (ru) | 2004-10-08 | 2008-11-20 | Новартис АГ (CH) | Комбинация органических соединений |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| US20080318922A1 (en) | 2004-12-24 | 2008-12-25 | Dainippon Sumitomo Pharma Co., Ltd. | Bicyclic Pyrrole Derivatives |
| KR20080000665A (ko) * | 2005-04-22 | 2008-01-02 | 알란토스 파마슈티컬즈 홀딩, 인코포레이티드 | 디펩티딜 펩티다아제-ⅳ 억제제 |
| AU2006265975B2 (en) | 2005-07-01 | 2011-12-15 | Merck Sharp & Dohme Corp. | Process for synthesizing a CETP inhibitor |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| BRPI0620643A2 (pt) | 2005-12-23 | 2011-12-20 | Novartis Ag | compostos de heterocìclicos condensados úteis como inibidores de dpp-iv, formulações farmacêuticas, produtos e usos dos compostos |
| BRPI0711558A2 (pt) | 2006-05-04 | 2011-11-08 | Boeringer Ingelheim Internat Gmbh | polimorfos |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| WO2008017670A1 (en) | 2006-08-08 | 2008-02-14 | Boehringer Ingelheim International Gmbh | Pyrrolo [3, 2 -d] pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| UY32177A (es) * | 2008-10-16 | 2010-05-31 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético |
| KR20110135411A (ko) * | 2009-03-27 | 2011-12-16 | 브리스톨-마이어스 스큅 컴퍼니 | Ｄｐｐ-ｉｖ 억제제로 주요 유해 심장혈관 이벤트를 예방하는 방법 |
| US20120219623A1 (en) * | 2009-10-02 | 2012-08-30 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions comprising bi-1356 and metformin |
| PH12012501037A1 (en) * | 2009-11-27 | 2013-01-14 | Boehringer Ingelheim Int | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
| US9034883B2 (en) * | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| US20130303462A1 (en) * | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
| JP6374862B2 (ja) * | 2012-05-24 | 2018-08-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 自己免疫性糖尿病、特に、ｌａｄａの治療に使用するためのｄｐｐ−４阻害剤としてのキサンチン誘導体 |
-
2014
- 2014-03-14 JP JP2015562201A patent/JP2016510795A/ja active Pending
- 2014-03-14 AU AU2014230096A patent/AU2014230096C1/en active Active
- 2014-03-14 EP EP24158250.1A patent/EP4364796A3/en active Pending
- 2014-03-14 EP EP20177745.5A patent/EP3744327A1/en not_active Withdrawn
- 2014-03-14 CN CN201910138358.3A patent/CN110075098A/zh active Pending
- 2014-03-14 BR BR112015020209A patent/BR112015020209A2/pt not_active Application Discontinuation
- 2014-03-14 CN CN201480012505.8A patent/CN105188706A/zh active Pending
- 2014-03-14 CA CA2903577A patent/CA2903577C/en active Active
- 2014-03-14 MX MX2015011466A patent/MX2015011466A/es unknown
- 2014-03-14 US US14/210,801 patent/US20140274889A1/en not_active Abandoned
- 2014-03-14 EP EP18177793.9A patent/EP3409279A1/en not_active Withdrawn
- 2014-03-14 KR KR1020157025351A patent/KR20150128726A/ko not_active Ceased
- 2014-03-14 WO PCT/EP2014/055113 patent/WO2014140284A1/en not_active Ceased
- 2014-03-14 EA EA201500934A patent/EA037712B1/ru unknown
- 2014-03-14 KR KR1020217024640A patent/KR20210099201A/ko not_active Ceased
- 2014-03-14 EP EP14709969.1A patent/EP2968344A1/en not_active Withdrawn
-
2015
- 2015-07-21 IL IL240064A patent/IL240064A0/en unknown
- 2015-08-24 CL CL2015002369A patent/CL2015002369A1/es unknown
- 2015-09-02 MX MX2021014242A patent/MX2021014242A/es unknown
- 2015-09-10 PH PH12015502042A patent/PH12015502042A1/en unknown
- 2015-12-08 US US14/962,343 patent/US20160089373A1/en not_active Abandoned
-
2016
- 2016-11-21 US US15/357,091 patent/US20170065596A1/en not_active Abandoned
-
2018
- 2018-05-22 US US15/985,861 patent/US20180263990A1/en not_active Abandoned
-
2019
- 2019-02-12 JP JP2019022289A patent/JP2019112409A/ja active Pending
- 2019-02-28 US US16/288,374 patent/US20190192523A1/en not_active Abandoned
- 2019-05-16 AU AU2019203445A patent/AU2019203445A1/en not_active Abandoned
-
2020
- 2020-07-10 US US16/925,456 patent/US20200338086A1/en not_active Abandoned
-
2021
- 2021-02-26 JP JP2021030485A patent/JP2021095409A/ja active Pending
- 2021-03-23 US US17/209,367 patent/US20210205316A1/en not_active Abandoned
-
2023
- 2023-10-02 US US18/375,639 patent/US20240033270A1/en not_active Abandoned
-
2024
- 2024-10-07 US US18/907,618 patent/US20250025470A1/en active Pending
-
2025
- 2025-04-28 JP JP2025074372A patent/JP2025115998A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016510795A5 (enExample) | ||
| JP6672365B2 (ja) | エンパグリフロジンの治療的使用 | |
| JP6325084B2 (ja) | エンパグリフロジンの治療的使用 | |
| JP2013529617A5 (enExample) | ||
| JP2015520155A5 (enExample) | ||
| JP2015517546A5 (enExample) | ||
| AU2023201872B2 (en) | Combinations of linagliptin and metformin | |
| Huebschmann et al. | Diabetes and advanced glycoxidation end products | |
| Parving et al. | Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design | |
| Scheen | Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes | |
| Lambers Heerspink et al. | Novel drugs and intervention strategies for the treatment of chronic kidney disease | |
| KR102159601B1 (ko) | 심방 확장 또는 재형성을 특징으로 하는 질환을 치료하기 위한 nep 억제제 | |
| DeFronzo et al. | Revitalization of pioglitazone: the optimum agent to be combined with a sodium‐glucose co‐transporter‐2 inhibitor | |
| US20240398818A1 (en) | Cardiosafe Antidiabetic Therapy | |
| Patoulias et al. | SGLT-2 inhibitors in type 1 diabetes mellitus: a comprehensive review of the literature | |
| JP2018527374A5 (enExample) | ||
| JP2022546987A (ja) | 代謝性疾患と闘うために使用される組成物およびその組成物の使用 | |
| Block et al. | Clinical trials with reno-vascular end points in patients with diabetes: Changing the scenario over the past 20 years | |
| Rajab et al. | Use of adjunctive glycaemic agents with vascular protective properties in individuals with type 1 diabetes: Potential benefits and risks | |
| EP3999041A1 (en) | Dose dumping resistant pharmaceutical compositions comrising verinurad | |
| JP2021185204A (ja) | 血管保護性及び心臓保護性抗糖尿病療法 | |
| Roman et al. | Type 2 Diabetes Mellitus | |
| Gatto et al. | From the SELECT study to SOUL: different administration methods of semaglutide but same efficacy? | |
| EP2755649B1 (fr) | Utilisation de la 3-(r)-[3-(2-methoxyphenylthio)-2-(s)-methyl-propyl]amino-3,4-dihydro-2h-1,5-benzoxathiepine pour la prevention et/ou le traitement des effets cardiotoxiques dus a la chimiotherapie et/ou les rayonnements | |
| Balaji et al. | Metabolic Syndrome and Its Effects on the Reno-Vascular System |